Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Dabigatran-Rivaroxaban'

Dabigatran-Rivaroxaban published presentations and documents on DocSlides.

A New Era in Anticoagulation Management
A New Era in Anticoagulation Management
by alexa-scheidler
Allyson Sarigianis, Pharm.D.. October 19, 2013. O...
Stroke, Bleeding, and
Stroke, Bleeding, and
by lois-ondreau
Mortality Risks . in . Elderly Medicare Beneficia...
New Oral Anticoagulant
New Oral Anticoagulant
by mitsue-stanley
R2 Patcharee Seesongsom. R2 . Sirada. . Phoja...
A New Era in Anticoagulation Management
A New Era in Anticoagulation Management
by debby-jeon
Allyson Sarigianis, Pharm.D.. October 19, 2013. O...
Novel Oral Anticoagulants
Novel Oral Anticoagulants
by natalia-silvester
(. N. OAC). Dan . Moellentin. , . PharmD. , BCPS,...
Dabigatran in Asia RE-LY Asia analysis and real world evidences from Asia
Dabigatran in Asia RE-LY Asia analysis and real world evidences from Asia
by adah
NOAC vs Warfarin Atrial Fibrillation Studies – A...
Dabigatran in myocardial injury after noncardiac
Dabigatran in myocardial injury after noncardiac
by lois-ondreau
surgery. Dr. PJ Devereaux on behalf of . MANAGE I...
DentalUpdateNovember 2015A New Generation of Antiplatelet and Anticoag
DentalUpdateNovember 2015A New Generation of Antiplatelet and Anticoag
by cecilia
Steven Johnston, BDS, MSc, MFDS RCS(Ed), Dental Of...
New (Direct)Oral anti-coagulants in the treatment of VTE
New (Direct)Oral anti-coagulants in the treatment of VTE
by ariel
Dr NA Smith - Haematology Dept. Heart of England...
Safe and Effective Use of Novel Oral Anticoagulants for Atrial Fibrillation: What You Need to Know
Safe and Effective Use of Novel Oral Anticoagulants for Atrial Fibrillation: What You Need to Know
by dsuser1
Christopher Granger, . MD. Sean Pokorney, MD. . D...
New Oral Anticoagulants: A Review
New Oral Anticoagulants: A Review
by phoebe-click
Babak Moini, MD. Veterans Affairs Hospital. Noon ...
The Novel Oral Anticoagulants
The Novel Oral Anticoagulants
by tatyana-admore
Fawaz Altuwaijri. ACEM trainee. Introduction. Cha...
Update on the New Oral Anticoagulants
Update on the New Oral Anticoagulants
by sherrill-nordquist
Eliot Williams, MD PhD. Division of Hematology &a...
Management of
Management of
by marina-yarberry
Atrial. Fibrillation. Phillip H. Lam, M.D.. Chie...
Thromboembolic protocols
Thromboembolic protocols
by cecilia
& safe anticoagulant prescribing. July 2020. D...
Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease:
Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease:
by giovanna-bartolotta
Rivaroxaban Plus Aspirin in Patients With and Wit...
A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban
A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban
by celsa-spraggs
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
Rivaroxaban or Aspirin for Extended Treatment of Venous Thr
Rivaroxaban or Aspirin for Extended Treatment of Venous Thr
by yoshiko-marsland
(EINSTEIN CHOICE). Ryan Sparks, . PharmD. , BCPS....
Rivaroxaban compared with enoxaparin for the prevention of
Rivaroxaban compared with enoxaparin for the prevention of
by luanne-stotts
Alexander T Cohen . On behalf of the MAGELLAN Ste...
NOACs vs. warfarin: Pros and Cons for Patients and Providers to Consider
NOACs vs. warfarin: Pros and Cons for Patients and Providers to Consider
by debby-jeon
Advantages of NOACs. No INR monitoring required. ...
Safety and Efficacy of Uninterrupted Anticoagulation with
Safety and Efficacy of Uninterrupted Anticoagulation with
by olivia-moreira
Dabigatran . Etexilate versus Warfarin in Patient...
Direct Oral Anticoagulants
Direct Oral Anticoagulants
by debby-jeon
Eliot Williams, MD PhD. Division of Hematology &a...
Anisah Ahmad Pharmacist
Anisah Ahmad Pharmacist
by genevieve
01904 72(4328). Anticoagulants . Warfarin . Novel ...
The thick and thin of it: Reviewing Anticoagulant Options
The thick and thin of it: Reviewing Anticoagulant Options
by oneill
Lanae Fox, . PharmD. , BCPS. I have no financial d...
Pharmacology of Anticoagulants
Pharmacology of Anticoagulants
by conchita-marotz
Nathan Culver, . PharmD. , BCPS. anticoagulant Me...
POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF
POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF
by phoebe-click
NOACS IN AF. Where Do We Stand With NOACs in AF ...
Oral anticoagulants in the 21
Oral anticoagulants in the 21
by natalia-silvester
st. century: A practical guide to using newer A...
Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding
Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding
by kyle585
Paul P. . Dobesh. , . Pharm.D. , FCCP, BCPS, BCCP....
Review on NOACs Studies Dr.
Review on NOACs Studies Dr.
by BlessedBeyondMeasure
Kourosh. . Sadeghi. Tehran University of medical ...
MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,
MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,
by HoneyBun
VTE death. ) for . rivaroxaban. vs. . enoxaparin....
X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the
X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the
by LittleMissPerfect
rivaroxaban. group vs. 1.02% of the vitamin K ant...
Rivaroxaban in stable peripheral or carotid artery disease
Rivaroxaban in stable peripheral or carotid artery disease
by basidell
Sonia Anand, on . behalf of the COMPASS Steering C...
A ssessment of D ual antiplatelet therapy versus
A ssessment of D ual antiplatelet therapy versus
by coursion
R. ivaroxaban . I. n atrial . F. ibrillation patie...
Ima A. Kusuma , MD, FIHA
Ima A. Kusuma , MD, FIHA
by hirook
“JIH. ” Hospital, Yogyakarta, Indonesia. The U...
A ssessment of D ual antiplatelet therapy versus
A ssessment of D ual antiplatelet therapy versus
by stefany-barnette
A ssessment of D ual antiplatelet therapy versus...
Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators
Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators
by yoshiko-marsland
Dr. Phil Wells on behalf of the EINSTEIN CHOICE ...
CAD/PAD in Primary Care CV Risk in Stable Outpatients
CAD/PAD in Primary Care CV Risk in Stable Outpatients
by stefany-barnette
Stratified by Baseline CV Risk Category. Aspirin ...
A Multicenter Randomized Trial Evaluating Clinically Signif
A Multicenter Randomized Trial Evaluating Clinically Signif
by giovanna-bartolotta
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
R eal-world
R eal-world
by liane-varnes
EVI. dence. on . S. troke prevention . I. n pati...
A Multicenter Randomized Trial Evaluating Clinically Signif
A Multicenter Randomized Trial Evaluating Clinically Signif
by ellena-manuel
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...